Live Breaking News & Updates on Jamesb Wyngaarden

Stay updated with breaking news from Jamesb wyngaarden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Medicine Grand Rounds | Duke Department of Medicine

Medicine Grand Rounds (MGR) is a weekly seminar series to support the academic environment of the Duke Department of Medicine. Topics and speakers are selected to provide faculty and trainees with up-to-date knowledge about timely issues in internal medicine. MGR occurs every Friday at 8 a.m in Duke North 2002 unless otherwise noted below at a different location. ....

United States , Naval Medical Center San Diego , San Diego , Johns Hopkins Myositiscenter , David Butterly , Jamesb Wyngaarden , Thomasw Leblanc , Nicholasj Rohrhoff , Martin Luther King Jr , Roya Roberts , Christopherj Hostler , Jessica Ma , Williamh Kane , George Barth Geller , Lisa Criscione Schreiber , Alexei Kudla , Diana Mcneill , Aimee Zaas , Darin Dufault , John Demis , Becky Smith , Michael Debaun , Lowell Henrylebermannendowed , Rodyp Cox , Behavioral Sciences , Durham Va Health Care System ,

Idera Pharmaceuticals (NASDAQ:IDRA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA – Get Rating) in a research note published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock. Shares of IDRA stock opened at $0.53 on Monday. Idera Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $1.71. […] ....

Paulc Zamecnik , Sudhira Agrawal , Jamesb Wyngaarden , Morgan Stanley , Geode Capital Management , Goldman Sachs Group Inc , Idera Pharmaceuticals Get Rating , Idera Pharmaceuticals Inc , Idera Pharmaceuticals , Renaissance Technologies , Get Rating , Sachs Group , Capital Management , Two Sigma Investments , Sigma Investments , Nasdaq Idra , Initiated Coverage , Stocknews Com ,

Idera Pharmaceuticals (NASDAQ:IDRA) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA – Get Rating) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock. IDRA opened at $0.54 on Friday. Idera Pharmaceuticals has a fifty-two week low of $0.40 and a fifty-two week high of $1.71. The company […] ....

Paulc Zamecnik , Sudhira Agrawal , Jamesb Wyngaarden , Morgan Stanley , Goldman Sachs Group Inc , Pricet Rowe Associates Inc , Idera Pharmaceuticals Get Rating , Idera Pharmaceuticals Inc , Idera Pharmaceuticals , Millennium Management , Get Rating , Sachs Group , Street Corp , Nasdaq Idra , Initiated Coverage , Stocknews Com ,

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA – Get Rating) have earned an average recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 12 month price target […] ....

Paulc Zamecnik , Sudhira Agrawal , Jamesb Wyngaarden , Virtu Financial , Idera Pharmaceuticals Inc , Renaissance Technologies , Vanguard Group Inc , Analyst Recommendations For Idera Pharmaceuticals , Marshall Wace , Idera Pharmaceuticals Get Rating , Idera Pharmaceuticals , Get Rating , Sigma Advisers , Nasdaq Idra ,